Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 registration study of BLU-782 in patients with Fibrodysplasia ossificans progressiva (FOP)

Trial Profile

A phase 2 registration study of BLU-782 in patients with Fibrodysplasia ossificans progressiva (FOP)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BLU-782 (Primary)
  • Indications Fibrodysplasia ossificans progressiva
  • Focus Registrational; Therapeutic Use
  • Sponsors Blueprint Medicines
  • Most Recent Events

    • 01 Aug 2019 According to a Blueprint Medicines media release, the company plans to initiate this trial by the end of 2019.
    • 27 Mar 2019 According to a Blueprint Medicines media release, the company plans to initiate this trial n the fourth quarter of 2019.
    • 27 Mar 2019 According to a Blueprint Medicines media release, this trial is one of the trials which will be funded by the net proceeds of the public offering announced today by the company.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top